{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:04:35Z","timestamp":1793210675434,"version":"4.5.0"},"reference-count":136,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin","award":["WMS-130\/S\/2024"],"award-info":[{"award-number":["WMS-130\/S\/2024"]}]},{"name":"the Pomeranian Medical University in Szczecin, Poland","award":["WMS-130\/S\/2024"],"award-info":[{"award-number":["WMS-130\/S\/2024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Modern lifestyle diseases remain a persistent challenge in healthcare. Currently, about 422 million people worldwide are affected by diabetes, while 1 in 8 people are living with obesity. The development of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has marked a significant milestone in treating these conditions. Interest in GLP-1RAs has grown due to evidence that, beyond their established role in diabetes management, these drugs influence other metabolic disorders. This is attributed to the fact that GLP-1 receptors are found in various healthy human tissues. However, a potential cause for concern is the expression of GLP-1 receptors in certain cancers. This review focuses on the most recent findings concerning the actions of GLP-1RAs, detailing their documented impact on the thyroid gland and pancreas. It addresses concerns about the long-term use of GLP-1RAs in relation to the development of pancreatitis, pancreatic cancer, and thyroid neoplasms by exploring the mechanisms and long-term effects in different patient subgroups and including data not discussed previously. This review was conducted through an examination of the literature available in the MedLine (PubMed) database, covering publications from 1978 to 10 May 2024. The collected articles were selected based on their relevance to studies of GLP-1 agonists and their effects on the pancreas and thyroid and assessed to meet the established inclusion criteria. The revised papers suggest that prolonged use of GLP-1RA could contribute to the formation of thyroid tumors and may increase the risk of acute inflammatory conditions such as pancreatitis, particularly in high-risk patients. Therefore, physicians should advise patients on the need for more frequent and detailed follow-ups.<\/jats:p>","DOI":"10.3390\/ph17111470","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T09:49:14Z","timestamp":1730454554000},"page":"1470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-6483","authenticated-orcid":false,"given":"Patrycja","family":"Kupnicka","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8658-4356","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Kr\u00f3l","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3477-3430","authenticated-orcid":false,"given":"Justyna","family":"\u017bychowska","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8441-054X","authenticated-orcid":false,"given":"Ryszard","family":"\u0141agowski","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9827-7114","authenticated-orcid":false,"given":"Eryk","family":"Prajwos","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-9259","authenticated-orcid":false,"given":"Anna","family":"Sur\u00f3wka","sequence":"additional","affiliation":[{"name":"Department of Plastic, Endocrine and General Surgery, Pomeranian Medical University, 72-010 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-4395","authenticated-orcid":false,"given":"Dariusz","family":"Chlubek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"ref_1","first-page":"154","article-title":"Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations","volume":"3","author":"Xu","year":"2007","journal-title":"Cardiovasc. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","article-title":"Incretin-based therapy: A powerful and promising weapon in the treatment of type 2 diabetes mellitus","volume":"2","author":"Koliaki","year":"2011","journal-title":"Diabetes Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2016.05.011","article-title":"Sensory Neurons that Detect Stretch and Nutrients in the Digestive System","volume":"166","author":"Williams","year":"2016","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.regpep.2004.06.018","article-title":"The physiological role of GLP-1 in human: Incretin, ileal brake or more?","volume":"128","author":"Schirra","year":"2005","journal-title":"Regul. Pept."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdi.12466","article-title":"Is GLP-1 a hormone: Whether and When?","volume":"7","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tan, Q., Akindehin, S.E., Orsso, C.E., Waldner, R.C., DiMarchi, R.D., M\u00fcller, T.D., and Haqq, A.M. (2022). Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.838410"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/1753-0407.12161","article-title":"Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic \u03b2-cells","volume":"6","author":"Ma","year":"2014","journal-title":"J. Diabetes."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: Current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2337\/diab.42.8.1215","article-title":"Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6","volume":"42","author":"Stoffel","year":"1993","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nature22378","article-title":"Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators","volume":"546","author":"Song","year":"2017","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10606820213687","article-title":"Structure-function of the glucagon receptor family of G protein-coupled receptors: The glucagon, GIP, GLP-1, and GLP-2 receptors","volume":"8","author":"Brubaker","year":"2002","journal-title":"Recept Channels"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Knudsen, L.B., and Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00155"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/en.2011-1070","article-title":"Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance","volume":"152","author":"Vendrell","year":"2011","journal-title":"Endocrinology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting","volume":"48","author":"Waser","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jdi.12463","article-title":"Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin\/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus","volume":"7","author":"Knudsen","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_23","first-page":"593","article-title":"Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats","volume":"12","author":"Malendowicz","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"ref_24","first-page":"237","article-title":"Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect","volume":"12","author":"Malendowicz","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00108-015-0002-x","article-title":"Treatment of type 2 diabetes","volume":"57","author":"Meier","year":"2016","journal-title":"Internist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chen, F., He, L., Li, J., Yang, S., Zhang, B., Zhu, D., Wu, Z., Zhang, S., Hou, D., and Ouyang, C. (2022). Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.879294"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"Birkenfeld","year":"2018","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs. Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wretlind, A., Zobel, E.H., de Zawadzki, A., Ripa, R.S., Curovic, V.R., von Scholten, B.J., Mattila, I.M., Hansen, T.W., Kj\u00e6r, A., and Vestergaard, H. (2022). Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Front. Clin. Diabetes Healthc., 3.","DOI":"10.3389\/fcdhc.2022.856485"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.32235","article-title":"A GLP-1\/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome","volume":"75","author":"Kim","year":"2022","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000446951","article-title":"Successful Pregnancy after Improving Insulin Resistance with the Glucagon-Like Peptide-1 Analogue in a Woman with Polycystic Ovary Syndrome: A Case Report and Review of the Literature","volume":"81","author":"Yang","year":"2016","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_42","unstructured":"(2024, September 05). Highlights of Prescribing Information. 2017, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/dme.12726","article-title":"Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes","volume":"32","author":"Greco","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"120370","DOI":"10.1016\/j.lfs.2022.120370","article-title":"Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway","volume":"294","author":"Liu","year":"2022","journal-title":"Life Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12022-023-09749-1","article-title":"The Thyroid Pathologist Meets Therapeutic Pharmacology","volume":"34","author":"Sande","year":"2023","journal-title":"Endocr. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk?","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: Pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/cen.14901","article-title":"The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes","volume":"99","author":"Tee","year":"2023","journal-title":"Clin. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e4251","DOI":"10.1210\/clinem\/dgab183","article-title":"Causal Association Between Serum Thyrotropin and Obesity: A Bidirectional, Mendelian Randomization Study","volume":"106","author":"Wang","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s11695-017-2965-2","article-title":"Effect of Bariatric Surgery on Thyroid Function in Obese Patients: A Systematic Review and Meta-Analysis","volume":"27","author":"Guan","year":"2017","journal-title":"Obes. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-13-0339","article-title":"Roux-en-Y gastric bypass and calorie restriction induce comparable time-dependent effects on thyroid hormone function tests in obese female subjects","volume":"169","author":"Lips","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000501895","article-title":"The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume","volume":"8","author":"Sencar","year":"2019","journal-title":"Eur. Thyroid. J."},{"key":"ref_57","first-page":"275","article-title":"Exenatide Treatment Reduces Thyroid Gland Volume, but Has No Effect on The Size of Thyroid Nodules","volume":"16","author":"Berker","year":"2020","journal-title":"Acta Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1385\/EP:12:4:365","article-title":"C-cell hyperplasia and medullary thyroid microcarcinoma","volume":"12","author":"Krueger","year":"2001","journal-title":"Endocr. Pathol."},{"key":"ref_59","first-page":"47","article-title":"A Study of Hormonal Abnormalities in Chronic Liver Disease","volume":"67","author":"Ray","year":"2019","journal-title":"J. Assoc. Physicians India"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Borges-Canha, M., Neves, J.S., Mendon\u00e7a, F., Silva, M.M., Costa, C., Cabral, P.M., Guerreiro, V., Louren\u00e7o, R., Meira, P., and Salazar, D. (2020). Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.572128"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1786559","DOI":"10.1155\/2022\/1786559","article-title":"Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms","volume":"2022","author":"Ye","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., and Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yang, Z., Lv, Y., Yu, M., Mei, M., Xiang, L., Zhao, S., and Li, R. (2022). GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.925377"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3803\/EnM.2021.1082","article-title":"Current Guidelines for Management of Medullary Thyroid Carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s12024-021-00407-8","article-title":"Medullary thyroid carcinoma with diabetic ketoacidosis: An autopsy case report and literature review","volume":"17","author":"Cheong","year":"2021","journal-title":"Forensic. Sci. Med. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/14737140.8.4.625","article-title":"RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer","volume":"8","author":"Lodish","year":"2008","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102834","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: A systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"924168","DOI":"10.1155\/2012\/924168","article-title":"A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer","volume":"2012","author":"Chiu","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4103\/IJPM.IJPM_478_17","article-title":"C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma","volume":"61","author":"Yadav","year":"2018","journal-title":"Indian. J. Pathol. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1677\/ERC-09-0136","article-title":"Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer","volume":"16","author":"Machens","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejphar.2012.07.024","article-title":"Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model","volume":"691","author":"Bulchandani","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2337\/dc17-1956","article-title":"No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for up to 5 Years in the LEADER Trial","volume":"41","author":"Sherman","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1210\/jc.2010-2318","article-title":"GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide","volume":"96","author":"Moses","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_77","first-page":"e33384","article-title":"Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism","volume":"15","author":"Zou","year":"2023","journal-title":"Cureus"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/ENDO:21:3:201","article-title":"Is calcitonin an important physiological substance?","volume":"21","author":"Hirsch","year":"2003","journal-title":"Endocrine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1365-2362.2002.01054.x","article-title":"Role of calcitonin in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in the rat","volume":"32","author":"Wang","year":"2002","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0192623312472402","article-title":"On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice","volume":"41","author":"Rosol","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3892\/ol.2017.5752","article-title":"Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine","volume":"13","author":"Song","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14715\/cmb\/2023.69.14.37","article-title":"GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells","volume":"69","author":"Zhang","year":"2023","journal-title":"Cell Mol. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645563"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","article-title":"Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years","volume":"161","author":"Randle","year":"2017","journal-title":"Surgery"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/thy.2010.0021","article-title":"Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006","volume":"21","author":"Ward","year":"2011","journal-title":"Thyroid"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: Management guidelines of the American Thyroid Association","volume":"19","author":"Chair","year":"2009","journal-title":"Thyroid"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1210\/endo.137.9.8756532","article-title":"Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line","volume":"137","author":"Crespel","year":"1996","journal-title":"Endocrinology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973\u20132002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3803\/EnM.2014.29.4.536","article-title":"Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance","volume":"29","author":"Jung","year":"2014","journal-title":"Endocrinol. Metab."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"146597","DOI":"10.1016\/j.gene.2022.146597","article-title":"GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the Egyptian population","volume":"834","author":"Elsayed","year":"2022","journal-title":"Gene"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/dom.15292","article-title":"Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study","volume":"26","author":"Bea","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-90-481-9060-7_1","article-title":"Overview of the pancreas","volume":"690","author":"Leung","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Gilbert, M.P., and Pratley, R.E. (2020). GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00178"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1463-1326.2009.01073.x","article-title":"The effects of glucagon-like peptide-1 on the beta cell","volume":"11","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Carlessi, R., Chen, Y., Rowlands, J., Cruzat, V.F., Keane, K.N., Egan, L., Mamotte, C., Stokes, R., Gunton, J.E., and Bittencourt, P.I.H. (2017). GLP-1 receptor signalling promotes \u03b2-cell glucose metabolism via mTOR-dependent HIF-1\u03b1 activation. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02838-2"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2146\/ajhp140260","article-title":"Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus","volume":"72","author":"Davis","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dot.2013.49.09.2020940","article-title":"Lixisenatide for the treatment of type 2 diabetes","volume":"49","author":"Petersen","year":"2013","journal-title":"Drugs Today"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14712598.2017.1296131","article-title":"Dulaglutide for the treatment of type 2 diabetes","volume":"17","author":"Scheen","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0002-9343(81)90579-9","article-title":"Insulin secretion in diabetes mellitus","volume":"70","author":"Pfeifer","year":"1981","journal-title":"Am. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus","volume":"25","author":"Brock","year":"2008","journal-title":"Diabet. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: Data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.diabres.2013.03.034","article-title":"A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes","volume":"100","author":"Tokuyama","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr. Pract."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dme.13160","article-title":"Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes","volume":"34","author":"Smits","year":"2017","journal-title":"Diabet. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, Lipase, and Acute Pancreatitis in People with Type 2 Diabetes Treated with Liraglutide: Results From the LEADER Randomized Trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMc0707137","article-title":"Exenatide and rare adverse events","volume":"358","author":"Cure","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: A systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/MPA.0b013e31824e67a3","article-title":"Exenatide-induced chronic damage of pancreatic tissue in rats","volume":"41","author":"Yu","year":"2012","journal-title":"Pancreas"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pds.3542","article-title":"Glucagon-like peptide 1-based therapies and risk of pancreatitis: A self-controlled case series analysis","volume":"23","author":"Li","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","article-title":"Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide","volume":"25","author":"Dore","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/dom.12230","article-title":"A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs","volume":"16","author":"Funch","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer","volume":"98","author":"Alves","year":"2012","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1464-5491.2012.03652.x","article-title":"Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: A follow-up study","volume":"29","author":"Wenten","year":"2012","journal-title":"Diabet. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/10600280231205490","article-title":"Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration","volume":"58","author":"Wilhite","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"121502","DOI":"10.1016\/j.lfs.2023.121502","article-title":"Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice","volume":"319","author":"Cardoso","year":"2023","journal-title":"Life Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.molmed.2015.04.005","article-title":"Type 2 diabetes as a protein misfolding disease","volume":"21","author":"Ukherjee","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_129","first-page":"e38630","article-title":"Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs--FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/gut.2008.149179","article-title":"The natural history of hereditary pancreatitis: A national series","volume":"58","author":"Rebours","year":"2009","journal-title":"Gut"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: Contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-023-03433-4","article-title":"Glucose-dependent inflammatory responses in obese compared to lean individuals","volume":"81","author":"Lundqvist","year":"2023","journal-title":"Endocrine"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Asiri, A., Al Qarni, A., and Bakillah, A. (2024). The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights. Diagnostics, 14.","DOI":"10.20944\/preprints202408.1919.v1"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/DMSO.S188856","article-title":"Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks","volume":"12","author":"Shemesh","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:54Z","timestamp":1760113614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":136,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111470"],"URL":"https:\/\/doi.org\/10.3390\/ph17111470","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}